Clinical experience with ezetimibe/simvastatin in a Mediterranean population

References

• World Health Organization. European health for all database, 2003. Available at: http://www.euro.who.int/hfadb (accessed October 2008)
   Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003;326:1423-30
   PubMed Web of Science ®Google Scholar
• Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia – report of the Program on the Surgical Control of Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-55
   PubMed Web of Science ®Google Scholar
• Study Group, European Atherosclerosis Society. The recognition and management of hyperlipidaemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988;9:571-600
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• The International Task Force for Prevention of Coronary Disease of the European Atherosclerosis Society. Prevention of coronary heart disease: scientific background and clinical guidelines. Nutr Metab Cardiovasc Dis 1992;2:113-56
   Google Scholar
• Rosenzweig JL, Ferrannini E, Scott M, et al. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3671-89
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Howard BV, Davidson M, et al. Lipoprotein management in patients with cardiometabolic risk. JACC 2008;51:1512-24
   Google Scholar
• EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72
   PubMed Web of Science ®Google Scholar
• Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung and Blood Institute. Circulation 2006;113:2363-72
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-On to Statin for Effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587-95
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study [published correction appears in Am Heart J 2005;149:882]. Am Heart J 2005;149:464-73
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94
   PubMed Web of Science ®Google Scholar
• Catapano A, Brady WE, King TR, et al. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005;21:1123-30
   PubMed Web of Science ®Google Scholar
• Davidson MH, Ballantyne CM, Kerzner B, et al, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:746-55
   PubMed Web of Science ®Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22:2041-53
   PubMed Web of Science ®Google Scholar
• Goldberg R, Guyton J, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: The VYTAL Study. Mayo Clin Proc 2006;81:1579-88
   PubMed Web of Science ®Google Scholar
• Roeters van Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin 2008;24(3):685-94
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al.; Meta-analysis of the cholesterol lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
   PubMed Web of Science ®Google Scholar
• Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. The epidemiology of Type 2 diabetes mellitus in Greek adults: the ATTICA study. Diabetic Med 2005; 22:1581-8
   PubMed Web of Science ®Google Scholar
• Athyros VG, Bouloukos VI, Pehlivanidis AN, et al.; MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 2005;7:397-405
   Google Scholar
• Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004;93:1481-6
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006;22:511-28
   PubMed Web of Science ®Google Scholar
• Hildemann S, Barho C, Karmann B, et al. Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr Med Res Opin 2007;23:713-19
   PubMed Web of Science ®Google Scholar
• Fras Z, Mikhailidis DP. Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Curr Med Res Opin 2008;24:2467-76
   PubMed Web of Science ®Google Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, et al. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183-92
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res (2009), doi:10.1016/j.phrs.2009.04.011
   Google Scholar
• Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006;10:851-66
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Anagnostopoulou KK, Salpea KD, et al. The prevalence of metabolic syndrome in various populations. Am J Med Sci 2007;333:362-71
   PubMed Web of Science ®Google Scholar